U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861894) titled 'Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC' on March 03.
Brief Summary: In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing management following neoadjuvant therapy with adebrelimab (anti-PD-L1) concurrent with chemoradiotherapy. The primary endpoint is 2-year overall survival rate in this watch-and-wait cohort.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Esophageal Squamous...